The Three P's: Parotid, PD-L1, and Pembrolizumab

We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid.

Detalles Bibliográficos
Autores principales: Wiggins, Amanda, Arter, Zhaohui, Kerns, Tamie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594310/
https://www.ncbi.nlm.nih.gov/pubmed/31308983
http://dx.doi.org/10.1155/2019/2305315
_version_ 1783430226240339968
author Wiggins, Amanda
Arter, Zhaohui
Kerns, Tamie
author_facet Wiggins, Amanda
Arter, Zhaohui
Kerns, Tamie
author_sort Wiggins, Amanda
collection PubMed
description We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid.
format Online
Article
Text
id pubmed-6594310
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-65943102019-07-15 The Three P's: Parotid, PD-L1, and Pembrolizumab Wiggins, Amanda Arter, Zhaohui Kerns, Tamie Case Rep Oncol Med Case Report We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid. Hindawi 2019-06-11 /pmc/articles/PMC6594310/ /pubmed/31308983 http://dx.doi.org/10.1155/2019/2305315 Text en Copyright © 2019 Amanda Wiggins et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Wiggins, Amanda
Arter, Zhaohui
Kerns, Tamie
The Three P's: Parotid, PD-L1, and Pembrolizumab
title The Three P's: Parotid, PD-L1, and Pembrolizumab
title_full The Three P's: Parotid, PD-L1, and Pembrolizumab
title_fullStr The Three P's: Parotid, PD-L1, and Pembrolizumab
title_full_unstemmed The Three P's: Parotid, PD-L1, and Pembrolizumab
title_short The Three P's: Parotid, PD-L1, and Pembrolizumab
title_sort three p's: parotid, pd-l1, and pembrolizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594310/
https://www.ncbi.nlm.nih.gov/pubmed/31308983
http://dx.doi.org/10.1155/2019/2305315
work_keys_str_mv AT wigginsamanda thethreepsparotidpdl1andpembrolizumab
AT arterzhaohui thethreepsparotidpdl1andpembrolizumab
AT kernstamie thethreepsparotidpdl1andpembrolizumab
AT wigginsamanda threepsparotidpdl1andpembrolizumab
AT arterzhaohui threepsparotidpdl1andpembrolizumab
AT kernstamie threepsparotidpdl1andpembrolizumab

Ejemplares similares